When was Biomeme founded?

Biomeme was founded in 2013 and raised its 1st funding round within a year of its incorporation.

Where is Biomeme located?

Biomeme is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania.

How many employees does Biomeme have?

As of Jul 31, 2026, the latest employee count at Biomeme is 64.

Is Biomeme a funded company?

Biomeme is a funded company, having raised a total of $6.2M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 15, 2013.

When was the latest funding round of Biomeme?

Biomeme's latest funding was a $***** Series A round on May 01, 2017, with participation from 0 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.9B in funding in 2026 to date.

Where does Biomeme rank among its competitors?

Biomeme ranks 52nd amongst 484 active competitors, of which 102 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Daye, which secured $576K in Nov, 2025.

Who are the top competitors of Biomeme?

Biomeme's top competitors include Molbio Diagnostics, Adaptive Biotechnologies and MeMed. Among them, Daye secured the most recent funding round in November, 2025.

Biomeme - 2026 Company Profile, Team, Funding & Competitors

Biomeme is a series A company based in Philadelphia (United States), founded in 2013 by Jesse vanWestrienen and Max Perelman. It operates as a Developer of a smartphone-based DNA detection platform. Biomeme has raised $6.2M in funding from Ben Franklin Technology Partners. The company has 484 active competitors, including 102 funded and 76 that have exited. Its top competitors include companies like Molbio Diagnostics, Adaptive Biotechnologies and MeMed.

Company Details

Developer of a smartphone-based DNA detection platform. The platform transforms mobile labs for advanced DNA diagnostics and real-time disease surveillance. The system includes a docking station for real-time qPCR, a mobile app to control the system and analyze results, and targeted test kits for preparing samples and identifying pathogens or diseases by their specific DNA or RNA signatures. The first application is a panel for diagnosing sexually transmitted diseases.

Website: biomeme.com
Social
Registered Address: Philadelphia, Pennsylvania

Key Metrics

Founded Year

2013

Location

Philadelphia, United States

Stage

Series A

Total Funding

$6.2M in 7 rounds

Latest Funding Round

Series A, May 01, 2017, $*****

Investors

Ben Franklin Technology Partners & 11 more

Ranked

52^nd among 484 active competitors

Employee Count

64 as on Jul 31, 2026

Investment & Acquisitions

Predigen

Similar Companies

Molbio Diagnostics & 492 more

View Biomeme's full profile

Biomeme is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Biomeme, Inc. CIN: 461268570 , United States, Active	Dec 31, 1999	-	47 (As on Dec 31, 2024)	-
BIOMEME, INC CIN: 46-1268570001 , United States, Active	Dec 31, 2012	-	202 (As on Dec 31, 2020)	-
Biomeme Inc CIN: 1596481 , United States, Active		$1M - $5M (As on May 01, 2017)	-	-

Biomeme has raised a total funding of $6.2M over 7 rounds. Its first funding round was on Jul 15, 2013. Biomeme has 12 institutional investors.

Here is the list of recent funding rounds of Biomeme:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 01, 2017	9580228	Series A	4516272	2468421	8300837	2455967
Sep 30, 2016	8258765	Grant (prize money)	3769417	2946085	1482660	EIC Fund
Jun 01, 2016	8198348	Grant (prize money)	7571756	2633459	7004497	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Biomeme's funding rounds and investors

The founders of Biomeme are Jesse vanWestrienen and Max Perelman.

Here are the details of Biomeme's key team members:

Jesse vanWestrienen: Co-Founder of Biomeme and founder of 1 other company.
Contact Info: 1 email address
Max Perelman: Co-Founder of Biomeme and founder of 1 other company.
Contact Info: 1 email address

View details of Biomeme's Founder profiles and Board Members

Biomeme's employee count trend

Biomeme has 64 employees as of Jul 26. Here is Biomeme's employee count trend over the years:

Uncover Biomeme's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Biomeme include Molbio Diagnostics, Adaptive Biotechnologies and MeMed. Here is the list of Top 10 competitors of Biomeme, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Molbio Diagnostics 2000, Salcete (India), Public	Developer of point-of-care molecular diagnostic platform for infectious disease detection	$124M	Motilal Oswal, Temasek & 36 others	73/100
2nd	Adaptive Biotechnologies 2009, Seattle (United States), Public	Provider of clinical diagnostics, and drug discovery for immune diseases	$419M	Viking Global Investors, Matrix & 21 others	72/100
3rd	MeMed 2009, Tirat Carmel (Israel), Series D	Provider of machine learning based diagnostic solutions for infectious diseases	$163M	La Maison Partners, Ping An & 23 others	69/100
4th	HaystackAnalytics 2018, Mumbai (India), Seed	Provider of genomics technology for personalized clinical decisions	$17.3M	STRIVE, Sun Pharma & 33 others	67/100
5th	Huwel Life 2015, Hyderabad (India), Series A	Molecular diagnostic solutions and products for the healthcare industry	$5.74M	Bartronics, BIRAC & 3 others	59/100
6th	Karius 2014, Redwood City (United States), Series C	Provider of diagnostics for identifying infectious diseases using microbial DNA	$315M	Khosla Ventures, Gilde Healthcare & 16 others	58/100
7th	Mylab 2016, Pune (India), Seed	Developer of diagnostic kits for pathogen detection and viral load monitoring	-	Rising Sun Holdings, Zydus Life & 10 others	57/100
8th	Seegene Technologies 2000, Seoul (South Korea), Public	Provider of advanced molecular diagnostics solutions	-	IMM Investment, Songhyun Investment & 3 others	56/100
9th	Daye 2018, London (United Kingdom), Series A	Manufacturer of period care products and provider of health tests	$19.2M	Salica Investments, Kindred Capital & 24 others	56/100
10th	Clear Labs 2014, Menlo Park (United States), Series D	Provider of food safety technologies for the identification of pathogens	$171M	Menlo Ventures, Redmile Group & 26 others	56/100
52nd	Biomeme 2013, Philadelphia (United States), Series A	Developer of a smartphone-based DNA detection platform	$6.2M	SeedFord Partners, Northwestern Mutual & 10 others	42/100